ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1532

Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience

Rossella Reggia1, Franco Franceschini1, Angela Tincani2 and Ilaria Cavazzana1, 1AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Abatacept, Effective, Rheumatoid arthritis (RA), safety and treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy the new subcutaneous (sc) formulation, that consists in a fixed dose of 125 mg of the drug, administered once weekly. Four clinical trials demonstrated an efficacy and a safety profile comparable to those obtained with the intravenous (iv) administration.

Aim of our work was to analyze the clinical response of a series of patients (pts) with RA treated with monthly iv infusion and than converted to the sc formulation.

Methods

We included 48 pts with RA, converted to the sc formulation of Abatacept from October 2013 to April 2014. We divided them into two groups, depending on their need to return to the iv administration for the appearance of a disease flare. The main clinical and serological features of the two groups were compared using the Chi-square, T-test or the Mann-Whitney test when appropriate.

Results

Pts converted to the sc formulation were the 48.5% of all cases receiving Abatacept therapy in our Unit. No pts received the iv “loading dose”. Eleven pts (22.9%) returned to the iv administration due to a disease flare (mean DAS 28: 2.35 vs 3.85, p:0.005), after a mean of 7.3 injections (range 4-14). The remaining 38 (77.1%) continued with the sc formulation. The compared parameters between the two groups are summarized in Table 1.

In pts with arthritis flare, disease activity decreased again (mean DAS 28: 2.45 vs 3.85, p:0.009) after returning to the iv administration of the drug (after a mean of 38.2 days).

One patient discontinued the sc formulation for the onset of related side-effects (headache and nausea) not reported with the iv administration.

Conclusion

although the safety profile of the sc formulation of Abatacept seems to confirm the data previously obtained with the iv use of the drug, a high rate of our patients complained a reduced efficacy and needed the return to the traditional way of administration.

We failed to identify clear risk factors that may help toward the selection of pts to which propose the formulation switch. However, if an arthritic flare occurs, the return to the iv administration seems to ensure a good control of the disease again. Therefore, the efficacy of the molecule does not seem to be compromised by an eventual switch failure.

Tab.1 Comparison between the clinical and serological features of patients with and without the need to return to the intravenous administration of Abatacept after the switch to subcutaneous formulation

Analyzed features

Pts who maintained the sc formulation

n=38 (77,5%)

Pts who returned to iv formulation

n=11 (22,5%)

p:

Mean age (years)

58.8

55.1

ns

Positivity for Rheumatoid Factor (RF)

n:34; (92%)

n:10; (91%)

ns

Positivity for anti-citrullinated protein antibodies (ACPA)

n:21; (70%)

n:8; (80%)

ns

Mean disease duration (months)

140.3

125.1

ns

Previous iv therapy duration (months)

20.8

17

ns

Body Max Index (BMI)

24.2

26.1

ns

Smokers

n:4; (10.5%)

n:3; (30%)

ns

DMARDs in association

n:33; (89.5%)

n:10; (90%)

ns

Previous use of biological agents

n:25; (65.8%)

n:8; (72.7%)

ns

N’ of different biological agents

used in the past: mean; [SD]

1.7; [1.6]

1.7; [2.3]

ns

Abatacept as first biological agent

n:13; (34.2%)

n:3; (27.3%)

ns

Remission of the disease at sc therapy start

n:29; (76.3%)

n:6; (54.5%)

ns

DAS28 at sc therapy start: mean; [SD]

2.07; [1.07]

2.35; [0.98]

ns

iv: intravenous, sc: subcutaneous, DMARDs: disease-modifying antirheumatic drugs, SD: standard deviation, ns: not significant.


Disclosure:

R. Reggia,
None;

F. Franceschini,
None;

A. Tincani,
None;

I. Cavazzana,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-the-subcutaneous-formulation-of-abataceptorencia-in-rheumatoid-arthritis-a-single-center-italian-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology